Champions Oncology Inc (CSBR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.01-0.79%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Champions Oncology aims to reach positive adjusted EBITDA this fiscal year. Revenue is expected near $65 million next year. The new CEO hired in 2025 brings stable leadership. The stock trades cheaply versus peers with a 5% free cash flow yield.
The company is currently loss-making and has missed earnings multiple times recently. Analysts expect revenue to decline about 7% next year. The CEO transition may not reverse weak execution. The business faces high risk and uncertain growth.
The market prices in about -7.5% revenue decline next year and a cautious outlook. Our fair value near $23.63 reflects modest recovery potential. We see some upside if adjusted EBITDA turns positive as planned.
Breaks if: adjusted EBITDA remains negative through FY26
Breaks if: CEO departs within 12 months
Breaks if: revenue falls below $60 million next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CSBR represents a speculative growth investment with a focus on expanding its healthcare offerings. The current thesis state is intact, despite recent earnings misses and a neutral financial performance.
The market currently prices CSBR as cheap compared to its peers, with a notable expectations gap. This suggests that investors are not overly optimistic about future performance, reflecting a cautious sentiment.
Management is focused on achieving positive adjusted EBITDA and driving revenue growth, which has shown some progress. However, the company remains loss-making, and near-term risks include a high probability of missing earnings expectations.
The thesis hinges on the company's ability to maintain revenue growth and achieve positive adjusted EBITDA while navigating potential economic headwinds. Additionally, performance of sector bellwethers could influence CSBR's trajectory.
The most important moves since the prior daily snapshot.
Valuation rose by 13.3 points (from 37.7 to 51.0).
Yes, our read has strengthened. The company outlined its fiscal 2027 plan, aiming for positive adjusted EBITDA. It also reported an earnings beat, supporting continued revenue growth. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EV/EBITDA rises above 20 or FCF yield falls below 3%
Over the next 1 to 3 years, CSBR's performance will depend on management execution and sector dynamics. Not investment advice.